Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1029
Primary information
GENEGUSB
NUMBER OF ASSAY142
ASSAY IDs238097 238096 326466 326465 326464 326463 326458 326457 326456 326451 98916 359647 454662 454664 454663 454661 208389 364926 364925 326461 86571 83590 79453 45108 364924 364923 326459 326452 86570 86569 83589 79452 79451 52515 45107 90625 180322 180321 359648 40449 1085840 454665 333450 147701 108138 108137 52516 160341 160340 160339 160338 160337 93435 477763 363650 343446 404892 333456 333454 333452 314841 306542 306541 306540 306539 166393 166392 144363 108139 160354 160353 91129 90626 160510 132834 132832 102993 102019 102018 679807 468194 468193 363651 343447 336802 1119097 1087098 492013 404893 337057 337053 337049 314842 289928 147702 144364 160355 1165427 1153850 90962 86722 1306825 1230052 1344224 1344223 42077 1254382 1129460 1309248 1292003 638947 607799 310996 310994 310865 294583 294581 187547 21678 21677 21676 21675 21674 21673 21672 779306 768615
Assay Name1. KM value using Escherichia coli beta-glucuronidase obtained at 370 C in MOPS buffer of pH 7.0,2. KM value using bovine liver beta-glucuronidase obtained at 370 C in MOPS buffer of pH 7.0,3. Cytotoxicity against human H298 cells assessed as inhibition of [3H]thymidine in presence of beta-glucuronidase after 48 hrs,4. Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine in presence of beta-glucuronidase after 48 hrs,5. Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine in presence of beta-glucuronidase after 48 hrs,6. Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine in presence of beta-glucuronidase after 48 hrs,7. Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs,8. Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs,9. Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs,10. Aqueous solubility in phosphate buffer at pH 4.0,11. Inhibitory activity was measured against murine L1210 leukemia cells.,12. Inhibition of bovine beta-glucuronidase,13. Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release,14. Inhibition of PMA-induced superoxide generation in Sprague-Dawley rat neutrophils,15. Inhibition of fMLP-induced superoxide generation in Sprague-Dawley rat neutrophils,16. Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release,17. Compound was evaluated for the binding affinity against T2 human cells; range 15-60 uM,18. Inhibition of Escherichia coli beta-glucuronidase,19. Inhibition of bovine liver beta-glucuronidase,20. Activity of Escherichia coli beta-glucuronidase,21. Cytotoxicity in the presence of beta-Glucuronidase (betaG, 5 micro g/ml) towards human hepatocellular cells (HepG2),22. Cytotoxicity in the presence of beta-Glucuronidase (betaG, 5 micro g/ml) towards human colorectal cells (HT-29),23. Cytotoxicity in the presence of beta-Glucuronidase (betaG, 5 micro g/ml) towards human lung carcinoma cells (H928),24. Cytotoxicity in the presence of beta-Glucuronidase (betaG, 5 micro g/ml) towards human cervical cells(CaSki),25. Inhibition of human Placental beta-N-acetylglucosaminidase,26. Inhibition of bovine kidney beta-N-acetylglucosaminidase,27. Cytotoxicity against human H298 cells assessed as inhibition of [3H]thymidine after 48 hrs,28. Aqueous solubility in phosphate buffer at pH 7.0,29. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]-thymidine into cellular DNA of human hepatocellular cells (HepG2),30. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human hepatocellular cells (HepG2),31. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human colorectal cells (HT-29),32. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human lung carcinoma cells (HT-29,33. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]-thymidine into cellular DNA of human lung carcinoma cells (H928),34. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human colorectal cells (COLO 205),35. Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human cervical cells (CaSki),36. Cytotoxicity against human melanoma A375 cells in culture in the absence of Escherichia coli glucuronidase, after incubation at 37 C for 72 h,37. Inhibitory effect of compound on superoxide anion generation in rat neutrophils stimulated with fMLP/CB,38. Inhibitory effect of compound on superoxide anion generation in rat neutrophils stimulated with PMA,39. Activity at bovine beta-glucuroniase by Lineweaver-Burke plot,40. Inhibitory effect of compound on the release of Beta-glucuronidase in rat neutrophils stimulated with fMLP/CB,41. Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucuronide as substrate incubated for 30 min prior to substrate addition by spectrophotometric analysis,42. Inhibition of LPS-induced nitric oxide accumulation in mouse RAW264.7 cells,43. Inhibition of compound 48/80-stimulated beta-glucuronidase release in rat peritoneal mast cell,44. Inhibitory activity against neutrophil degranulation by measuring the content of beta-glucuronidase in the supernatant,45. Inhibitory activity against mast cell degranulation by measuring the content of beta-glucuronidase in the supernatant,46. 50% inhibition against mast cell degranulation by measuring the content of beta-glucuronidase in the supernatant,47. Cytotoxicity in the presence of beta-Glucuronidase (betaG, 5 micro g/ml) towards human colorectal cells(COLO 205),48. Effective concentration to stimulate beta-glucuronidase release from human polymorphonuclear cells (PMN) (n=8),49. Effective concentration to stimulate beta-glucuronidase release from human polymorphonuclear cells (PMN) (n=6),50. Effective concentration to stimulate beta-glucuronidase release from human polymorphonuclear cells (PMN) (n=5),51. Effective concentration to stimulate beta-glucuronidase release from human polymorphonuclear cells (PMN) (n=4),52. Effective concentration to stimulate beta-glucuronidase release from human polymorphonuclear cells (PMN) (n=3),53. Release of beta-glucuronidase from human polymorphonuclear leukocytes(PMN),54. Cytotoxicity against human U87 cells assessed as viability in presence of beta glucuronidase,55. Antiproliferative activity against human NCI-H661 cells after 48 hrs,56. Cytotoxicity against human HT29 cells by MTT assay,57. Cytotoxicity against human A549 cells after 24 hrs visualized by Lofflers methylene blue by colony forming assay,58. Antiinflammatory activity against mouse N9 cells assessed as inhibition of LPS/IFN-gamma-induced nitrite accumulation after 24 hrs,59. Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs,60. Inhibition of compound 48/80-stimulated histamine release in rat mast cell,61. Inhibition of bovine kidney beta-N-acetylglucosaminidase,62. Cytotoxicity against CD70 positive Caki1 cells assessed as cell viability after 96 hrs,63. Cytotoxicity against CD30 positive L540 Cy cells assessed as cell viability after 96 hrs,64. Cytotoxicity against CD30 positive and CD70 negative L428 cells assessed as cell viability after 96 hrs,65. Cytotoxicity against CD30 positive Karpas 299 cells assessed as cell viability after 96 hrs,66. Inhibitory activity against TNF-alpha release in RAW 264.7 cells in the supernatant,67. 50% inhibition against TNF-alpha release in RAW 264.7 cells in the supernatant,68. 50% inhibition against TNF-alpha release in N9 cells in the supernatant,69. Inhibitory activity against mast cell degranulation by measuring the content of histamine in the supernatant,70. Tested for inhibition of binding of [125I]C5a to intact human polymorphonuclear cells (PMN) (n=3),71. Tested for inhibition of binding of [125I]C5a to intact human polymorphonuclear cells (PMN) (n=10),72. Effective concentration to induce smooth muscle contraction in human fetal artery,73. Cytotoxicity against human melanoma A375 cells in culture in the presence of Escherichia coli -glucuronidase,after incubation at 37 C for 72 h,74. Ability to induce shape change (polarization) in human polymorphonuclear leukocytes (PMN),75. Inhibitory effect of compound on the accumulation of NO2 in the culture media of RAW 264.7 cells in response to LPS,76. Inhibitory effect of compound on the accumulation of NO2 in the culture media of N9 cells in response to LPS/IFN-gamma,77. Inhibitory effect of compound on the release of lysozyme in rat neutrophils stimulated with fMLP/CB,78. Cytotoxicity of compound was determined against Lo Vo colon cancer cells in presence of GUS from Escherichia coli,79. Cytotoxicity of compound was determined against Lo Vo colon cancer cells,80. TP_TRANSPORTER: inhibition of Naf-GlcA uptake (Naf-GlcA: 0.1 uM) in bile canalicular membrane vesicles of Wistar rat,81. Cytotoxicity against human A2780 cells,82. Cytotoxicity against human BGC823 cells,83. Antiproliferative activity against human NCI-H661 cells after 48 hrs in presence of beta-glucuronidase,84. Cytotoxicity against human HT29 cells in presence of beta-glucuronidase by MTT assay,85. Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge,86. Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability after 3 days by XTT assay in presence of beta-glucuronidase,87. Inhibition of Escherichia coli beta-glucuronidase using para-nitrophenyl-beta-D-glucuronide as substrate incubated for 30 min prior to substrate addition measured for 30 min by spectrophotometric analysis,88. Antiinflammatory activity in rat PMNC assessed as inhibition of platelet-activating factor-induced beta-glucuronidase release,89. Cytotoxicity against human A549 cells after 24 hrs visualized by Lofflers methylene blue by colony forming assay in presence of beta-D-glucuronidase,90. Antiinflammatory activity in LPS/IFN-gamma-stimulated mouse N9 cells assessed as inhibition of nitric oxide production pretreated 1 hr before LPS/IFNgamma challenge,91. Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production pretreated 1 hr before LPS challenge,92. Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 min
ACTIVITYSubstance BioActivity: 2 Active, 2 Tested Substance BioActivity: 2 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 2 Active, 2 Activity <= 1 µM, 2 Tested Substance BioActivity: 2 Active, 2 Activity <= 1 µM, 2 Tested Substance BioActivity: 2 Active, 2 Activity <= 1 µM, 2 Tested Substance BioActivity: 1 Active, 2 Tested Substance BioActivity: 8 Active, 1 Activity <= 1 µM, 9 Tested Substance BioActivity: 2 Active, 3 Tested Substance BioActivity: 4 Active, 8 Tested Substance BioActivity: 1 Active, 8 Tested Substance BioActivity: 1 Active, 8 Tested Substance BioActivity: 4 Active, 8 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Tested Substance BioActivity: 2 Tested Substance BioActivity: 2 Tested Substance BioActivity: 2 Active,